Special Report: The Lab Kickback Risks of “Freebies”
How to avoid six common compliance risks involving free supplies, equipment, software, and other non-monetary compensation
Practical, “What-to-Do” and “How-to-Do-It” Help to Comply with the Latest State & Federal Laws, Rules & Regulations that Affect Your Diagnostic Lab or Pathology Practice
How to avoid six common compliance risks involving free supplies, equipment, software, and other non-monetary compensation
G2’s list of major FDA approvals includes cancer and liquid biopsy, COVID-19, STI, and neurologic tests.
Recent cases involve Medicare’s 14-Day Rule, improper PHI disclosure to a media outlet, kickbacks, and COVID-19 fraud.
Comments on the FDA’s proposed rule to regulate LDTs as in vitro diagnostic devices reveal mixed reactions.
Genialis CEO and co-founder Rafael Rosengarten, PhD, discusses key 2023 AI developments and what they could mean for laboratories.
Five strategies for lab leaders to focus on to tackle the challenges of today and ensure future success.
Standard 1910.1450 requires labs to have a chemical hygiene plan.
Approaching laboratory safety from a diversity, equity, inclusion, and accessibility perspective.
With US STI cases continuing to climb to numbers not seen in decades, a recent FDA approval comes at an opportune moment.
The basics of how the OSHA inspection process works and how laboratories can successfully navigate it.
A settlement for kickback allegations, prison time for lab owners convicted of COVID-19 fraud, and 10x Genomics gets OK for lawsuit.